Profil
Mr. Peter Olagunju is a Chief Executive Officer at ImmunoScape Pte Ltd. and a Chairman at March Biosciences, Inc. Mr. Olagunju was previously employed as a Chief Operating Officer by TCR² Therapeutics, Inc., a Senior Vice President-Technical Operations by FerGene, Inc., a Vice President-Global Patient Operations by bluebird bio, Inc., a Head-Quality by Dendreon Corp., and a Head-Quality by ZymoGenetics, Inc. He received his undergraduate degree from the University of Illinois At Urbana–Champaign and an MBA from Foster School of Business.
Aktive Positionen von Peter Olagunju
| Unternehmen | Position | Beginn |
|---|---|---|
ImmunoSCAPE Pte Ltd.
ImmunoSCAPE Pte Ltd. BiotechnologyHealth Technology Operates as a pre-clinical biotechnology company focused on the discovery and development of next-generation TCR-T cell therapies | Vorstandsvorsitzender | 23.09.2026 |
Ehemalige bekannte Positionen von Peter Olagunju
| Unternehmen | Position | Ende |
|---|---|---|
FerGene, Inc.
FerGene, Inc. BiotechnologyHealth Technology Develops gene therapies for the treatment of unresponsive non-muscle invasive bladder cancer | Corporate Officer/Principal | 01.07.2021 |
| GENETIX BIOTHERAPEUTICS, INC. | Corporate Officer/Principal | 01.03.2020 |
ZymoGenetics, Inc.
ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology Develops protein based drugs | Corporate Officer/Principal | - |
| DENDREON CORPORATION | Corporate Officer/Principal | - |
| TCR2 THERAPEUTICS INC. | Geschäftsführer | - |
Ausbildung von Peter Olagunju
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 8 |
|---|---|
Dendreon Corp.
Dendreon Corp. Medical SpecialtiesHealth Technology Discovers, develops and commercializes novel products for the treatment of cancer | Health Technology |
ZymoGenetics, Inc.
ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology Develops protein based drugs | Health Technology |
bluebird bio, Inc.
bluebird bio, Inc. BiotechnologyHealth Technology Develops genetic therapies based on blood stem cells | Health Technology |
TCR2 Therapeutics, Inc.
TCR2 Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage cell therapy company which engages in the development of biological drugs and engineering T-cells for cancer therapy | Health Technology |
University of Illinois At Urbana–Champaign
University of Illinois At Urbana–Champaign Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
ImmunoSCAPE Pte Ltd.
ImmunoSCAPE Pte Ltd. BiotechnologyHealth Technology Operates as a pre-clinical biotechnology company focused on the discovery and development of next-generation TCR-T cell therapies | Health Technology |
FerGene, Inc.
FerGene, Inc. BiotechnologyHealth Technology Develops gene therapies for the treatment of unresponsive non-muscle invasive bladder cancer | Health Technology |
Foster School of Business
Foster School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
















